Intellectual Property Contracts & Agreements
10,148 Contracts & Agreements
Intellectual property agreements include contracts relating to copyrights, trademarks, patents, and other inventions.
Browse by Subcategory
- License Agreements (9,557 contracts from 2,763 companies)
- Trademark Agreements (591 | 364)
- Aerospace & Defense (25 contracts from 9 companies)
- Air Freight & Logistics (7 | 3)
- Airlines (4 | 2)
- Auto Components (11 | 10)
- Automobiles (11 | 7)
- Banks (10 | 8)
- Beverages (18 | 6)
- Biotechnology (2,950 | 520)
- Building Products (14 | 9)
- Capital Markets (202 | 26)
- Chemicals (84 | 26)
- Commercial Services & Supplies (43 | 19)
- Communications Equipment (28 | 16)
- Construction & Engineering (7 | 2)
- Construction Materials (1 | 1)
- Consumer Finance (9 | 6)
- Containers & Packaging (7 | 2)
- Distributors (3 | 2)
- Diversified Consumer Services (24 | 6)
- Diversified Financial Services (9 | 7)
- Diversified Telecommunication Services (8 | 6)
- Electric Utilities (10 | 5)
- Electrical Equipment (49 | 16)
- Electronic Equipment, Instruments & Components (45 | 21)
- Energy Equipment & Services (82 | 43)
- Entertainment (73 | 15)
- Equity Real Estate Investment Trusts (REITs) (32 | 15)
- ETFs (88 | 50)
- Food Products (53 | 23)
- Food & Staples Retailing (6 | 4)
- Gas Utilities (1 | 1)
- Health Care Equipment & Supplies (655 | 180)
- Health Care Providers & Services (222 | 82)
- Health Care Technology (31 | 16)
- Hotels, Restaurants & Leisure (90 | 38)
- Household Durables (40 | 14)
- Household Products (3 | 2)
- Independent Power & Renewable Electricity Producers (3 | 2)
- Industrial Conglomerates (6 | 2)
- Insurance (18 | 14)
- Interactive Media & Services (28 | 17)
- Internet & Direct Marketing Retail (19 | 12)
- IT Services (40 | 16)
- Leisure Products (17 | 11)
- Life Sciences Tools & Services (168 | 28)
- Machinery (22 | 15)
- Media (73 | 18)
- Metals & Mining (50 | 18)
- Mortgage REITs, Lenders, & Securities (11 | 8)
- Multiline Retail (1 | 1)
- Oil, Gas & Consumable Fuels (96 | 37)
- Paper & Forest Products (5 | 1)
- Personal Products (68 | 28)
- Pharmaceuticals (1,251 | 279)
- Professional Services (17 | 10)
- Real Estate Management & Development (5 | 4)
- Road & Rail (2 | 2)
- Semiconductors & Semiconductor Equipment (94 | 34)
- Software (205 | 62)
- SPACs, Investment, & Acquisition Companies (136 | 56)
- Specialty Retail (28 | 14)
- Technology Hardware, Storage & Peripherals (27 | 11)
- Textiles, Apparel & Luxury Goods (48 | 13)
- Thrifts & Mortgage Finance (3 | 1)
- Tobacco (8 | 2)
- Trading Companies & Distributors (4 | 3)
- Transportation Infrastructure (1 | 1)
- Water Utilities (4 | 3)
- Wireless Telecommunication Services (10 | 4)
- Unassigned Industry (2,725 | 1,059)
- Amendment to License Agreement with Monarch Media (Blue Line Holdings, Inc., Filed With SEC on November 19, 2024)
- License Agreement with Monarch Media, LLC (Blue Line Holdings, Inc., Filed With SEC on November 19, 2024)
- Amendment to License Agreement (Comstock Mining Inc., Filed With SEC on November 19, 2024)
- Nonexclusive License Agreement between Neurogene Inc. and the Board of Trustees of the Leland Stanford Junior University dated August 6, 2024 (AQUINOX PHARMACEUTICALS, INC, Filed With SEC on November 18, 2024)
- Exclusive License Agreement, dated July 10, 2024, between Akos Biosciences, Inc. and Aries Science and Technology, LLC (AMERI Holdings, Inc., Filed With SEC on November 14, 2024)
- Fourth Amendment to Exclusive License Agreement (Sensitization of Solid Tumors), dated November 13, 2024, by and between Enviro Therapeutics Inc. and Cedars-Sinai Medical Center (Kairos Pharma, LTD., Filed With SEC on November 14, 2024)
- Third Amendment to Exclusive License Agreement (RelA of NF-kB), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (Kairos Pharma, LTD., Filed With SEC on November 14, 2024)
- Third Amendment to Exclusive License Agreement (Fibrosis), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (Kairos Pharma, LTD., Filed With SEC on November 14, 2024)
- Fourth Amendment to Exclusive License Agreement (Depletion of DNA), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center and Enviro... (Kairos Pharma, LTD., Filed With SEC on November 14, 2024)
- Third Amendment to Exclusive License Agreement (Cancer Autoimmune), dated November 13, 2024, by and between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center (Kairos Pharma, LTD., Filed With SEC on November 14, 2024)
- Fifth Amendment to Data License Agreement dated September 26, 2024 (SURF AIR MOBILITY INC., Filed With SEC on November 14, 2024)
- Storage License Agreement by and among the Company, BKPBIOTECH, Inc. and JLSA2 Therapeutics, Inc., dated as of September 23, 2024 (Dynamics Special Purpose Corp., Filed With SEC on November 14, 2024)
- Amendment 4 to Exclusive License Agreement, dated October 28, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Spero Therapeutics, Inc., Filed With SEC on November 14, 2024)
- Amendment No. 2 to Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated March 6, 2018 (DURECT CORP, Filed With SEC on November 14, 2024)
- Amendment No. 1 to Exclusive License Agreement between the Company and Virginia Commonwealth University Intellectual Property Foundation dated July 2, 2015 (DURECT CORP, Filed With SEC on November 14, 2024)
- First Amendment to the License Agreement, dated as of October 2, 2024, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc (Liquidia Corp, Filed With SEC on November 13, 2024)
- Device License Agreement, dated as of October 2, 2024, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc (Liquidia Corp, Filed With SEC on November 13, 2024)
- Exclusive License Agreement (PBML04), dated July 31, 2024, by and between the Registrant and Gemma Biotherapeutics, Inc (Passage BIO, Inc., Filed With SEC on November 13, 2024)
- Exclusive License Agreement (PBKR03), dated July 31, 2024, by and between the Registrant and Gemma Biotherapeutics, Inc (Passage BIO, Inc., Filed With SEC on November 13, 2024)
- Exclusive License Agreement (PBGM01), dated July 31, 2024, by and between the Registrant and Gemma Biotherapeutics, Inc (Passage BIO, Inc., Filed With SEC on November 13, 2024)
- Amendment No. 2 to License Agreement, dated August 7, 2024, by and between Immunome, Inc. and Bristol-Myers Squibb Company (Immunome Inc., Filed With SEC on November 13, 2024)
- Amendment No. 4 to License Agreement, dated September 27, 2024, by and between the Broad Institute, Inc. and the Registrant (Prime Medicine, Inc., Filed With SEC on November 12, 2024)
- First Amendment to Option and License Agreement, by and between Registrant and AstraZeneca Ireland Limited, dated September 30, 2024 (Voyager Therapeutics, Inc., Filed With SEC on November 12, 2024)
- First Amendment to Option and License Agreement, by and between Registrant and Novartis Pharma AG, dated September 3, 2024 (Voyager Therapeutics, Inc., Filed With SEC on November 12, 2024)
- First Amendment to the License Agreement by and between Bayer Aktiengesellschaft and Pulmovant, Inc., dated as of September 22, 2023 (Roivant Sciences Ltd., Filed With SEC on November 12, 2024)
- License Agreement by and between Bayer Aktiengesellschaft and Pulmovant, Inc., dated as of July 27, 2023 (Roivant Sciences Ltd., Filed With SEC on November 12, 2024)
- Amended and Restated License Agreement by and between Registrant and Paragon Therapeutics, Inc. dated as of September 20, 2024 (MIRAGEN THERAPEUTICS, INC., Filed With SEC on November 12, 2024)
- License Agreement between the Company and Genentech, Inc., dated August 2, 202 (SANGAMO THERAPEUTICS, INC, Filed With SEC on November 12, 2024)
- Sixth Amendment to License Agreement by and between the Company and President and Fellows of Harvard College, dated as of August 28, 2024 (Sana Biotechnology, Inc., Filed With SEC on November 8, 2024)
- Amendment No. 2 to Amended and Restated License Agreement by and between the Company and the University of Rochester, dated as of May 30, 2024 (Sana Biotechnology, Inc., Filed With SEC on November 8, 2024)
- License Agreement dated September 11, 2024, by and between the Registrant and Princeton 202 Associates Limited Partnership (Y-mAbs Therapeutics, Inc., Filed With SEC on November 8, 2024)
- Second Amended and Restated License Agreement, dated as of November 6, 2024, by and between Hilton Worldwide Holdings Inc. and Hilton Grand Vacations Inc (Hilton Grand Vacations Inc., Filed With SEC on November 8, 2024)
- Addendum to the Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated August 1, 2024, by and between the Company and Aroa Biosurgery Ltd (TELA Bio, Inc., Filed With SEC on November 8, 2024)
- License Agreement, dated as of October 17, 2024, by and between Lomond Therapeutics, Inc. and Bala Therapeutics, Inc (Venetian-1 Acquisition Corp., Filed With SEC on November 7, 2024)
- License Agreement, dated as of October 17, 2024, by and between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc (Venetian-1 Acquisition Corp., Filed With SEC on November 7, 2024)
- Patent License Agreement by and between the Company and Intract Pharma Limited dated September 11, 2024 (Hillstream BioPharma Inc., Filed With SEC on November 7, 2024)
- Amendment #1 to License Agreement, dated August 30, 2024, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS (Akebia Therapeutics, Inc., Filed With SEC on November 7, 2024)
- License Agreement, entered into on October 29, 2024 and effective October 23, 2024, by and between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd (Y-mAbs Therapeutics, Inc., Filed With SEC on November 4, 2024)
- License Agreement between (Vir Biotechnology, Inc., Filed With SEC on November 4, 2024)
- Option and License Agreement by and between IDEAYA Biosciences, Inc. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd., dated July 30, 2024 (IDEAYA Biosciences, Inc., Filed With SEC on November 4, 2024)
